Skip to main content
. 2013 Dec 7;5(2):363–374. doi: 10.18632/oncotarget.1620

Figure 6. EFEMP1 expression correlates to TMZ treatment efficacy and survival in glioblastoma patients.

Figure 6

A, EFEMP1 expression levels in multiple publicly available glioblastoma datasets as visualized by using R2 (R2.amc.n1). Glioblastoma datasets (red) [28–34] were compared to normal brain (grey) [27]. [Number of patients] included in dataset are shown. B, survival of glioblastoma patients with high- (red and green), or low (blue and purple) EFEMP1 expression was plotted for TMZ-treated (n=82, upper panel) or non-treated (n=70, lower panel) patients (www.rembrandt.org). C, EFEMP1 mRNA expression levels in patient samples upon clinical progression following TMZ treatment (post-TMZ), compared to matching samples biopsied at diagnosis (pre-TMZ). Numbers (#) represent individual glioblastoma patients. Expression levels were normalized to expression in non-neoplastic brain tissue. Shown are averages, error bars indicate SD. *p<0.05 t test.